Topic: Cancer treatment
Immunotherapy is yet to make a substantial impact on treatment for advanced breast cancer, A/Professor Swarbrick wants to understand why.
This project has worked to improve treatments and reduce the major challenge of some breast cancer patients’ resistance to endocrine therapy and relapse.
Dr Wang and her team have identified a new treatment target for one of the most lethal forms of leukaemia.
Dr Micklethwaite has been developing myeloma-specific CAR T-cells – immune cells specifically designed to recognise and destroy myeloma cells.
Prof Tangye is studying patients with immune deficiencies and how this leads to the development of lymphoma cancers.
Professor Croucher and his team have demonstrated the potential of a newly approved treatment for osteoporosis to strengthen and rebuild bone damaged by myeloma.
Associate Professor Phoebe Phillips and her team have come up with a new way to target the cells that help the spread of aggressive pancreatic cancer.
This project will develop methods for upscaling CAR T-cell production in NSW – accelerating the introduction of this cutting-edge therapy and making treatment more affordable.
Associate Professor Holst’s team have been working on a new type of anti-cancer drug that can ‘starve’ prostate cancer cells and stop their growth.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.